The latest ovarian cancer news and blogs from Target Ovarian Cancer, including fundraising, campaigns, research and support news, and blogs from people affected by ovarian cancer. Scroll down for our events listings, including support and fundraising events.

Information is correct at the time of publication, please note information in historical news stories around drug availability or statistics may not still be relevant.

Monday 12 January 2015
In today’s news the Cancer Drugs Fund (CDF) has announced the results of its recent review of over 50 cancer drugs, including four ovarian cancer drugs. The review included a re-evaluation of drugs that are currently funded by the CDF, as well as an evaluation of new applications for funding. The...
Monday 22 December 2014
The National Institute for Health and Care Excellence (NICE) have today published the draft guidance on their recent Multiple Technology Appraisal of certain ovarian cancer drugs. The NICE committee has been consulting on a review of the use of topotecan (Hycamtin), pegylated liposomal doxorubicin...
Friday 19 December 2014
You may have read or heard the news that the drug olaparib (to be marketed as Lynparza) has been approved by the European Commission, to be used by women with platinum-sensitive relapsed BRCA1 or BRCA2 mutated high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who...
Annwen Jones
Tuesday 18 November 2014
We’re delighted to announce that Annwen Jones, Chief Executive of Target Ovarian Cancer, has been invited to join the Cancer Drugs Fund (CDF) Panel. The CDF provides £280m each year to enable patients in England to access drugs that are not routinely funded by the NHS, including bevacizumab (...